Codexis, Inc. (CDXS)
Codexis, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Codexis, Inc. (CDXS) is a Biotechnology company based in US with a market capitalization of $200M. Revenue grew 18.6% year-over-year and free cash flow was negative at -$23.8M. This page tracks CDXS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 188 employees · IPO Apr 22, 2010
Valuation
Valuation & price
$2.46as of May 17, 2026· -20.9% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
3.96
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$200M
Market cap
18.6%
Revenue growth (YoY)
86.7%
Gross margin
-$23.8M
Free cash flow (USD)
-$5M
Net debt
Net cash position
18.7%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
1
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 23, 2026Filing
Earnings Release
- 8-K eventJun 22, 2026Filing
Annual Meeting Results
- Insider sellJun 11, 2026Filing
Insider Sell $6KDe Vre Raymond · Director · $6.2K
- 8-K eventMay 7, 2026Filing
Earnings Release
- Quarterly reportMay 7, 2026Filing
10-Q Filed
- 8-K eventApr 14, 2026Filing
Board Resignation and Rebalance
Questions
Frequently asked questions
What is Codexis, Inc.'s market cap?
Codexis, Inc. (CDXS) has a market capitalization of $200M.
What is CDXS's P/E ratio?
A meaningful P/E ratio is not available for CDXS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is CDXS's price-to-book (P/B) ratio?
CDXS trades at 3.96 times book value per share.
Are insiders buying CDXS stock?
SEC Form 4 filings show no open-market insider buys at Codexis, Inc. in the last 90 days (1 sell).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.